Q2 EPS Estimates for CVS Health Decreased by Leerink Partnrs

CVS Health Co. (NYSE:CVS - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of CVS Health in a research report issued to clients and investors on Thursday, May 1st. Leerink Partnrs analyst M. Cherny now forecasts that the pharmacy operator will post earnings of $1.45 per share for the quarter, down from their previous forecast of $1.54. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share. Leerink Partnrs also issued estimates for CVS Health's Q3 2025 earnings at $1.19 EPS, Q4 2025 earnings at $1.27 EPS, FY2025 earnings at $6.16 EPS, FY2026 earnings at $7.17 EPS, FY2027 earnings at $8.29 EPS and FY2028 earnings at $9.39 EPS.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.31 EPS.

A number of other research analysts have also issued reports on CVS. UBS Group upped their target price on shares of CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday. Cantor Fitzgerald raised shares of CVS Health from a "neutral" rating to an "overweight" rating in a research note on Wednesday, February 12th. Edward Jones raised CVS Health from a "hold" rating to a "buy" rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. lifted their price objective on CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research report on Tuesday, February 18th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and an average price target of $74.81.

CVS Health Price Performance

Shares of NYSE:CVS traded down $0.79 on Monday, hitting $66.32. The company had a trading volume of 6,984,481 shares, compared to its average volume of 11,466,938. The company has a market cap of $83.61 billion, a PE ratio of 18.12, a PEG ratio of 0.98 and a beta of 0.60. The business has a 50 day moving average of $66.79 and a 200 day moving average of $58.81. CVS Health has a 52-week low of $43.56 and a 52-week high of $72.51. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were paid a $0.665 dividend. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.01%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

Insider Activity at CVS Health

In other news, Director Michael F. Mahoney acquired 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.22% of the company's stock.

Institutional Trading of CVS Health

A number of hedge funds have recently made changes to their positions in CVS. Assetmark Inc. boosted its stake in CVS Health by 38.2% during the 1st quarter. Assetmark Inc. now owns 533,803 shares of the pharmacy operator's stock valued at $36,165,000 after acquiring an additional 147,655 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of CVS Health by 8.2% during the first quarter. Cetera Investment Advisers now owns 344,963 shares of the pharmacy operator's stock worth $23,371,000 after purchasing an additional 26,184 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in CVS Health by 25.7% in the first quarter. Avantax Advisory Services Inc. now owns 160,764 shares of the pharmacy operator's stock worth $10,892,000 after purchasing an additional 32,873 shares in the last quarter. Tempus Wealth Planning LLC acquired a new stake in CVS Health during the first quarter valued at approximately $215,000. Finally, One Wealth Advisors LLC bought a new position in CVS Health during the 1st quarter worth approximately $234,000. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.